Buyback yield (TTM)
N/A
Shareholder yield (TTM)
N/A
5Y share count change
2.0%
Buyback spend (TTM)
N/A
Cumulative buybacks
$5.35B
Key takeaways
- Diluted share count is up 2.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
Dividend & buyback yield over time for Moderna (MRNA)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Moderna (MRNA)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Moderna (MRNA)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Moderna (MRNA)
Latest: $0.00
Overview
In 2025, Moderna (MRNA) buyback spend totalled $0.00.
Moderna buyback spend peaked at $3.33B in 2022; the latest annual figure is $0.00 in 2025 (100.0% below peak).
The highest annual buyback spend of $3.33B was reported in 2022. The lowest in the available history was $0.00 in 2016.
Moderna Buyback Spend 2025: $0.00
Moderna buyback spend in 2025 was $0.00.
Moderna Buyback Spend 2024: $0.00
Moderna buyback spend in 2024 was $0.00, plunged 100.0% below 2023.
Moderna Buyback Spend 2023: $1.15B
2023's buyback spend for Moderna came in at $1.15B, plunged 65.4% below 2022.
Moderna Buyback Spend 2022: $3.33B
Moderna posted buyback spend of $3.33B in 2022, surged 288.4% from 2021. This figure represents the highest annual value in the available history.
Moderna Buyback Spend 2021: $857.00M
Moderna buyback spend in 2021 was $857.00M.
See more financial history for Moderna (MRNA).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $483.00M | −$483.00M | — | 0.39B | +1.3% | |
| 2024 | $0.00 | $429.00M | −$429.00M | — | 0.38B | +0.5% | |
| 2023 | $1.15B | $305.00M | $848.00M | 3.04% | 0.38B | -8.2% | |
| 2022 | $3.33B | $226.00M | $3.10B | 4.81% | 0.42B | -3.5% | |
| 2021 | $857.00M | $142.00M | $715.00M | 0.83% | 0.43B | +13.0% | |
| 2020 | $0.00 | $93.00M | −$93.00M | — | 0.38B | +15.3% | |
| 2019 | $2.89M | $81.12M | −$78.23M | 0.04% | 0.33B | +0.6% | |
| 2018 | $8.18M | $72.56M | −$64.38M | 0.16% | 0.33B | -12.6% | |
| 2017 | $0.00 | $40.05M | −$40.05M | — | 0.38B | +486.6% | |
| 2016 | $0.00 | $39.36M | −$39.36M | — | 0.06B | — |
- 2025$0.00
- 2024$0.00
- 2023$1.15B
- 2022$3.33B
- 2021$857.00M
- 2020$0.00
- 2019$2.89M
- 2018$8.18M
- 2017$0.00
- 2016$0.00
Buybacks vs stock-based compensation for Moderna (MRNA)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Moderna (MRNA)
How Moderna splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Moderna, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation